KR101948337B1 - 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체 - Google Patents

증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체 Download PDF

Info

Publication number
KR101948337B1
KR101948337B1 KR1020137014351A KR20137014351A KR101948337B1 KR 101948337 B1 KR101948337 B1 KR 101948337B1 KR 1020137014351 A KR1020137014351 A KR 1020137014351A KR 20137014351 A KR20137014351 A KR 20137014351A KR 101948337 B1 KR101948337 B1 KR 101948337B1
Authority
KR
South Korea
Prior art keywords
leu
ser
glu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137014351A
Other languages
English (en)
Korean (ko)
Other versions
KR20140114266A (ko
Inventor
치 콩 라이
로디 케빈 스태퍼드
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20140114266A publication Critical patent/KR20140114266A/ko
Application granted granted Critical
Publication of KR101948337B1 publication Critical patent/KR101948337B1/ko
Assigned to 다케다 야쿠힌 고교 가부시키가이샤 reassignment 다케다 야쿠힌 고교 가부시키가이샤 권리의 전부이전등록 Assignors: 박스알타 인코퍼레이티드, 박스앨타 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020137014351A 2010-11-05 2011-11-04 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체 Active KR101948337B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
US61/410,437 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (2)

Publication Number Publication Date
KR20140114266A KR20140114266A (ko) 2014-09-26
KR101948337B1 true KR101948337B1 (ko) 2019-02-14

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137014351A Active KR101948337B1 (ko) 2010-11-05 2011-11-04 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체

Country Status (18)

Country Link
US (2) US9150637B2 (https=)
EP (1) EP2635297B1 (https=)
JP (1) JP5922141B2 (https=)
KR (1) KR101948337B1 (https=)
CN (1) CN103298483B (https=)
AU (1) AU2011323236B2 (https=)
BR (1) BR112013011041B1 (https=)
CA (1) CA2816575C (https=)
CO (1) CO6720990A2 (https=)
DK (1) DK2635297T3 (https=)
EA (1) EA035447B1 (https=)
ES (1) ES2721478T3 (https=)
IL (1) IL226158B (https=)
MX (2) MX347503B (https=)
MY (1) MY165089A (https=)
SG (2) SG10201509149VA (https=)
WO (1) WO2012061689A2 (https=)
ZA (1) ZA201303816B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123200A1 (en) 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506076A (ja) 1999-08-09 2003-02-18 ノース・キャロライナ・ステイト・ユニヴァーシティ トリ始原生殖細胞を使用して、未分化のトリ細胞培養物を取得する方法
JP2003508019A (ja) 1999-05-20 2003-03-04 エモリー ユニバーシテイ 修飾されたｖｉｉｉ因子

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
WO1999029848A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
DK1194161T3 (da) 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
WO2003031598A2 (en) * 2001-10-05 2003-04-17 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
AU2002364509A1 (en) 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2009075772A1 (en) * 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508019A (ja) 1999-05-20 2003-03-04 エモリー ユニバーシテイ 修飾されたｖｉｉｉ因子
JP2003506076A (ja) 1999-08-09 2003-02-18 ノース・キャロライナ・ステイト・ユニヴァーシティ トリ始原生殖細胞を使用して、未分化のトリ細胞培養物を取得する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. J. Biochem. Vol. 240. pp365-372 (1996).

Also Published As

Publication number Publication date
CN103298483A (zh) 2013-09-11
US20130296244A1 (en) 2013-11-07
IL226158A0 (en) 2013-06-27
BR112013011041A2 (pt) 2017-06-06
KR20140114266A (ko) 2014-09-26
EA201390654A1 (ru) 2014-01-30
EP2635297A4 (en) 2014-06-25
SG10201509149VA (en) 2015-12-30
EP2635297A2 (en) 2013-09-11
AU2011323236A1 (en) 2013-06-06
US20150353625A1 (en) 2015-12-10
JP2013545459A (ja) 2013-12-26
BR112013011041B1 (pt) 2021-05-25
EP2635297B1 (en) 2019-02-27
ZA201303816B (en) 2021-05-26
CN103298483B (zh) 2017-04-12
DK2635297T3 (da) 2019-05-06
MY165089A (en) 2018-02-28
CO6720990A2 (es) 2013-07-31
MX351220B (es) 2017-10-05
IL226158B (en) 2019-08-29
CA2816575C (en) 2019-06-11
ES2721478T3 (es) 2019-07-31
US10053500B2 (en) 2018-08-21
MX2013005047A (es) 2013-12-06
MX347503B (es) 2017-04-26
WO2012061689A2 (en) 2012-05-10
AU2011323236B2 (en) 2017-03-30
JP5922141B2 (ja) 2016-05-24
US9150637B2 (en) 2015-10-06
CA2816575A1 (en) 2012-05-10
SG190136A1 (en) 2013-07-31
EA035447B1 (ru) 2020-06-17
AU2011323236A8 (en) 2013-07-25
WO2012061689A3 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
KR102097263B1 (ko) Viii 인자 조성물 및 이를 제조하고 사용하는 방법
JP3495365B2 (ja) ブタ第ｖｉｉｉ因子ａ２ドメインをコードするｄｎａ
EP2291523B1 (en) Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
US5663060A (en) Hybrid human/animal factor VIII
KR20150144803A (ko) 복합체
LOLLAR The association of factor VIII with von Willebrand factor
CN111183151B (zh) 因子viii亚种的纯化
JP2005511038A (ja) 第ｖｉｉｉ因子ｃ２ドメインのバリアント
KR101948337B1 (ko) 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
Kemball‐Cook et al. The behaviour of different factor VIII concentrates in a chromogenic factor X‐activating system
CA2771328A1 (en) Cofactors for thrombin activation of factor vii and uses thereof
HK1189486A (en) A new variant of antihemophilic factor viii having increased specific activity
HK1189486B (en) A new variant of antihemophilic factor viii having increased specific activity
Krishnan et al. Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII Δ II
EP3785726A1 (en) Factor viii protein with increased half-life
AU2013202564A1 (en) Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
WO1995013301A1 (en) Cross-linked factor viii
HK1151068B (en) Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
HK1058946B (en) Hybrid human/porcine factor viii

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130604

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20160422

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161031

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171216

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180921

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180921

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180516

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20181126

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20181029

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180921

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180516

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190208

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220125

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230126

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240130

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250210

Start annual number: 7

End annual number: 7